Clinical trial · no report yet · Phase 2
JAKARTA2
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
- NCT01523171 ↗
- Terminated
- Bristol-Myers Squibb
- 36 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 21 | |
| Podcasts | 13 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Hematopoietic Neoplasm
- Interventions
- SAR302503
- Arms
- SAR302503 400 mg · Experimental
- Enrollment
- 97
- Primary outcomes
- Response Rate: Percentage of Participants With >=35% Reduction From Baseline in Spleen Volume at End of Cycle 6
- Sponsor
- Bristol-Myers Squibb
- Start
- Apr 30, 2012
- Primary completion
- Apr 30, 2014
- Results posted
- Yes
- Registry record
- NCT01523171 · updated Jul 16, 2026
Publications
linked from the registry- Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8. PubMed 28602585